| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF) | Phase 3 | — | Small Molecules | Respiratory System | ||
Phase 3 data readout example | Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF) | Phase 3 | — | Small Molecules | Respiratory System | ||
Phase 3 data readout example | Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF) | Phase 3 | — | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
United Therapeutics Corporation$544.33
+6.03 (+1.12%)
A 83Pipeline Score Undervalued Biotech · Commercial
Market Cap
24.13 B
EPS
29.33
P/E Ratio
20.98 $
Value Trade
178.76 M
SEC Financials
Q1 2026Dilution Risk
Revenue
781.50 M
R&D Expenses
138.20 M
Operating CF
463.30 M
Total Assets
6.71 B
Total Liabilities
813.10 M
Equity
5.90 B
D/E Ratio
12,345
-1.4 %
Week
-0.92 %
1 Month
18.64 %
3 Month
20.08 %
6 Month
196.46 %
5 Year
8,321.19 %
All Time
Cash Data
Cash Position
2.15 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
1.08 M
52 Week Range
272.12 - 609.35
% held by Insiders
3.47 %
% held by Institutions
99.12 %
Enterprise Value
21.97 B
Total Shares
42.46 M
Short %
5.69 %
Float Shares
38.51 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
A83
Pipeline Score $32.5B
Pipeline ValueUndervalued
Valuation Signal88
Drugs Scored4.5x
rNPV / MCap Top 98%
Mid Cap (rank 19 of 905)
Percentile RankUnited Therapeutics Corporation earns an A-grade pipeline score (83/100), with $38.2B risk-adjusted pipeline value, led by ALVAC-HIV vCP1521 + AIDSVAX in HIV Infection (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALVAC-HIV vCP1521 + AIDSVAX Monoclonal antibody | HIV Infection | Phase 3 | NCT00223080 | 72% | $7.0B | COMPLETED | 16,402 | - | - | Jun 1, 2009 | - | Apr 24, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ralinepag | pulmonary arterial hypertension | Phase 3 | 2025-06-23 | |||
ralinepag | pulmonary arterial hypertension | Phase 3 | 2025-06-23 | |||
ralinepag | pulmonary arterial hypertension | Phase 3 | 2025-06-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in UTHR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
United Therapeutics Corporation (UTHR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UTHR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
UTHR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
UTHRUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
United Therapeutics Corporation is scheduled to present at the Jefferies Global Healthcare Conference. The details regarding the presentation or any specific topics to be discussed were not provided in the article. This event is an opportunity for the company to engage with investors and stakeholders in the healthcare sector.
Read more →UTHRUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics Corporation announced the publication of the TETON-1 study of Tyvaso in The New England Journal of Medicine. The study findings were also presented at the ATS 2026 conference. This marks a significant step for the company in showcasing its research efforts.
Read more →UTHRUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics Corporation announced the presentation of the ADVANCE OUTCOMES study of Ralinepag at the ATS 2026 conference. The study's findings were highlighted, showcasing the company's ongoing commitment to advancing treatments for pulmonary arterial hypertension. Further details about the study's outcomes and implications were not disclosed in the announcement.
Read more →UTHRUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation is scheduled to present at the RBC Capital Markets Global Healthcare Conference. The presentation will provide insights into the company's current initiatives and future directions. Details regarding the timing and content of the presentation have not been disclosed in the article.
Read more →UTHRUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
United Therapeutics Corporation presented new data from their studies TETON-1 and ADVANCE OUTCOMES, along with additional research on pulmonary hypertension and pulmonary fibrosis at the ATS 2026 conference. The details of the findings were not disclosed in the article. This presentation highlights the company's ongoing commitment to advancing research in these areas.
Read more →UTHRUnited Therapeutics Corporation Reports First Quarter 2026 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported its financial results for the first quarter of 2026, indicating a 2% decrease in total revenues compared to the same quarter in 2025. Net income also fell by 15%, attributed to lower sales from several products, particularly Nebulized Tyvaso. However, the company highlighted positive clinical outcomes from recent studies and plans for new developments, particularly with ralinepag DPI. This suggests ongoing commitment to growth in the therapeutic space despite short-term revenue declines.
Read more →UTHRUnited Therapeutics Corporation Reports First Quarter 2026 Financial Results
United Therapeutics Corporation reported a 2% decrease in total revenues for Q1 2026, totaling $781.5 million. Despite this decline, the company announced positive results from its ADVANCE OUTCOMES and TETON-1 clinical studies, which may enhance future growth. The firm is also advancing development plans for ralinepag DPI, aiming for once-daily dosing to expand its therapeutic reach.
Read more →UTHRUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
United Therapeutics Corporation announced that Professor Raymond Dwek will retire from its Board of Directors at the 2026 Annual Meeting. Dwek has been a member since 2002, during which the company's share price increased significantly. He will continue to serve on the Scientific Advisory Board, and the Board will reduce its size from 13 to 12 members.
Read more →UTHRUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
United Therapeutics Corporation will report its first quarter 2026 financial results on May 6, 2026. A press release will be issued at 6:30 a.m. ET, followed by a public webcast at 9:00 a.m. ET. The webcast will be accessible for one year post-event. The company is known for its innovative approaches to rare diseases and organ transplantation.
Read more →UTHRUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
United Therapeutics Corporation presented 11 new data presentations at the ISHLT 2026 meeting, focusing on advancements in pulmonary hypertension treatment and organ transplantation. Key findings from the ARTISAN and PHINDER studies suggest that early detection and aggressive treatment can significantly improve patient outcomes. The company also highlighted innovative approaches in xenotransplantation and ex vivo lung perfusion.
Read more →UTHRUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
United Therapeutics has received FDA Regenerative Medicine Advanced Therapy designation for miroliverELAP®, aimed at treating acute liver failure. This designation is expected to expedite the development and review process, highlighting the therapy's potential in addressing a critical health issue. The move underscores the company's commitment to innovative treatments in the biopharma sector.
Read more →UTHRUnited Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
United Therapeutics Corporation announced that its TETON-1 pivotal study for Tyvaso® has met its primary endpoint in treating idiopathic pulmonary fibrosis. The study's results exceeded the treatment effect observed in the previous TETON-2 study. This success may provide significant advancements in the management of this condition.
Read more →UTHRUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
United Therapeutics Corporation has announced a $2 billion stock repurchase program, including a $1.5 billion Accelerated Share Repurchase (ASR) agreement with Citibank. The company aims to enhance shareholder value and believes there is a disconnect between its fundamentals and market valuation. The remaining $500 million will be available for additional repurchases at the company's discretion over the next year.
Read more →UTHRUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program Agreements for aggregate $1.5 billion Accelerate
United Therapeutics Corporation has announced a significant $2 billion stock repurchase authorization and initiated a $1.5 billion Accelerated Share Repurchase program. This financial move is aimed at enhancing shareholder value, reflecting the company's confidence in its growth trajectory and operational strength. The ASR program will involve complex agreements with Citibank, including an uncollared and a collared agreement to optimize share repurchases. The company retains additional authorization for further repurchases, aiming to opportunistically return capital to shareholders.
Read more →UTHRUnited Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
United Therapeutics Corporation will present an overview and update at the Leerink Global Healthcare Conference on March 9, 2026. CEO Martine Rothblatt will lead the presentation, which can be accessed via a live webcast. The company is known for its innovative approaches to treating rare diseases and expanding organ transplant options.
Read more →UTHRUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
United Therapeutics Corporation announced that its pivotal phase 3 ADVANCE OUTCOMES study demonstrated that ralinepag significantly reduced the risk of clinical worsening in pulmonary arterial hypertension (PAH) patients by 55% compared to placebo. The study also showed notable improvements in secondary endpoints such as six-minute walk distance. The treatment was well-tolerated, reinforcing its potential as a new therapeutic option for PAH.
Read more →UTHRUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
United Therapeutics Corporation reported a record revenue of $3.18 billion for the year 2025, marking an 11% increase from 2024. The growth was primarily driven by strong sales of Tyvaso and Orenitram, with expectations for continued double-digit growth. The company is also anticipating pivotal data from its ADVANCE OUTCOMES and TETON-1 clinical programs, which could lead to new treatment options for patients.
Read more →UTHRUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported its financial results for Q4 and the full year of 2025, announcing record revenues of $3.18 billion, an 11% increase from 2024. The company's revenue growth was primarily driven by the success of its Tyvaso product line, which saw continued market share expansion. Looking forward, United Therapeutics is optimistic about upcoming pivotal data from its ADVANCE OUTCOMES and TETON-1 clinical programs, which may offer significant new treatment options for patients. Overall, the company's strong financial performance reflects effective commercial strategies and a commitment to innovation.
Read more →UTHRUnited Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
United Therapeutics Corporation will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. Michael Benkowitz, the President and COO, will provide an overview and update during the session. The presentation will be available via live webcast and archived for later access. The company is committed to innovating for patient needs and operates as a public benefit corporation.
Read more →UTHRUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
United Therapeutics Corporation will report its fourth quarter and full year 2025 financial results on February 25, 2026. A press release will be issued at 6:30 a.m. ET, followed by a public webcast at 9:00 a.m. ET. The company emphasizes its commitment to innovation and social responsibility as a public benefit corporation.
Read more →UTHRUnited Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
United Therapeutics announced positive results from its Phase 1 study of miroliverELAP, an external liver assist product for patients with acute liver failure. The study demonstrated safety and survival benefits, leading to plans for a Phase 2 study. This innovative approach addresses the critical need for organ alternatives in liver failure cases.
Read more →UTHRUnited Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
United Therapeutics Corporation has appointed Dr. Kevin J. Tracey to its Board of Directors. Dr. Tracey, a leader in inflammation and bioelectronic medicine, brings significant expertise and entrepreneurial experience. His appointment is seen as a strategic move to enhance the company's mission in developing therapies for rare pulmonary diseases and organ manufacturing.
Read more →UTHRUnited Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
United Therapeutics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Dr. Martine Rothblatt will provide an overview and update during the session. The presentation will be accessible via a live webcast, with an archived version available afterward. The company emphasizes its mission to innovate for patient needs.
Read more →UTHRUnited Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported record financial results for the third quarter of 2025, reflecting a 7% revenue increase to $799.5 million compared to the previous year. Key products such as Tyvaso and Orenitram were significant contributors to this growth. Additionally, breakthrough study results in idiopathic pulmonary fibrosis could enhance the company’s market presence. However, there were declines in sales for certain products, indicating areas to monitor moving forward.
Read more →UTHRUnited Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis Positive results were observed across all subgroup
United Therapeutics Corporation announced positive results from the TETON-2 pivotal study of Tyvaso for treating idiopathic pulmonary fibrosis (IPF). The study successfully met its primary efficacy endpoint, showing a statistically significant improvement in forced vital capacity (FVC) compared to placebo. Benefits of Tyvaso were consistent across various patient subgroups, and additional secondary endpoints also demonstrated statistically significant improvements. The company plans to use these results to support a supplemental New Drug Application to the FDA for IPF indications.
Read more →UTHRUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics' balance sheet and confidence in its near-term prosp
United Therapeutics Corporation has announced a $1 billion accelerated share repurchase program, reflecting confidence in its balance sheet and future prospects. The company has entered into two ASR agreements with Citibank, one collared and one uncollared, to repurchase its shares. An initial payment will be made on August 4, 2025, with further settlement expected in late 2025 for the uncollared agreement and early 2026 for the collared one. This initiative showcases United Therapeutics' commitment to returning value to shareholders while maintaining growth potential.
Read more →UTHRUnited Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results Record total revenue of $799 million, reflecting 12 percent growth over the second quarter of 2024 and 12 consecu
United Therapeutics Corporation reported record financial results for Q2 2025, with total revenues of $798.6 million, up 12% from the previous year. The growth was driven by strong sales of Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. The company also announced a share repurchase program worth up to $1 billion, signaling confidence in its long-term financial prospects. Looking forward, the completion of Phase 3 studies for several therapies is anticipated to enhance treatment options for patients with pulmonary diseases.
Read more →UTHRUnited Therapeutics Corporation Reports First Quarter 2025 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported a strong financial performance for the first quarter of 2025, with total revenues increasing by 17% year-over-year to $794.4 million. The rise in revenue was primarily driven by significant growth in Tyvaso sales. The company anticipates continued momentum with upcoming clinical readouts for TETON 2 and the initiation of the UKidney clinical study. Additionally, United Therapeutics is advancing its efforts to create an unlimited supply of transplantable organ alternatives.
Read more →UTHRUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported a strong financial performance for the fourth quarter and full year of 2024, achieving a record revenue of $2.88 billion, reflecting a 24% increase from the previous year. CEO Martine Rothblatt highlighted the company's successful execution of clinical studies and FDA approval for a new xenotransplantation initiative this month. The company expects continued momentum in 2025, backed by effective sales and education efforts for its pulmonary hypertension treatments. Robust growth was noted particularly in its Tyvaso product line, which is crucial for addressing patient needs in this therapeutic area.
Read more →UTHRUnited Therapeutics: Enabling Inspiration J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025 2 INTRODUCTION Safe Harbor Statement MIROKIDNEY®, MIROLIVERELAP®, ORENITRAM®, REMODULIN®, TYVASO®, and
United Therapeutics presented at the J.P. Morgan Healthcare Conference, highlighting its strong financial performance and innovative pipeline. The company emphasized a commitment to improving patient outcomes and addressing the organ shortage crisis through its organ alternatives platform. Significant regulatory and clinical catalysts are anticipated from 2025, underscoring the potential for expansion in its market. United Therapeutics aims to leverage its robust cash flow to support ongoing innovation in rare diseases and organ transplantation technologies.
Read more →UTHRUnited Therapeutics Corporation Reports Third Quarter 2024 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported a significant increase in third quarter revenues for 2024, rising 23% to $748.9 million compared to the same quarter in 2023. The company's CEO highlighted the achievement of a $3 billion annual revenue run rate and anticipates continued growth through upcoming clinical studies and regulatory events. Key drivers for revenue include the strong sales of Tyvaso products, particularly following their commercial launch. However, the company is facing challenges, including a significant litigation liability and a decrease in Remodulin revenue.
Read more →UTHRUnited Therapeutics Corporation Reports Second Quarter 2024 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation announced its financial results for Q2 2024, showing a 20% year-over-year increase in total revenues reaching $714.9 million. The company reported record revenue for the fifth straight quarter, driven largely by the success of its product Tyvaso in treating pulmonary hypertension. However, the cost of sales also rose significantly, potentially impacting future profitability, and sales of Adcirca experienced a notable decline. The company remains optimistic about its innovative clinical pipeline and organ manufacturing initiatives.
Read more →UTHRUnited Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors SILVER SPRING, Md. and
United Therapeutics Corporation has elected Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors. Her extensive experience in health policy and public health is expected to benefit the company's mission of innovating treatments for end-stage organ diseases. Malcolm's background includes contributions during the COVID-19 pandemic and a record of tackling health disparities. This board change reflects United Therapeutics' strategy to enhance its governance with new expertise.
Read more →UTHRUnited Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation announced its financial results for the first quarter of 2024, reporting total revenues of $677.7 million, a 34% increase compared to the same period last year. The growth was primarily driven by strong sales of their Tyvaso products following the launch of Tyvaso DPI in June 2022. The company also implemented a $1 billion accelerated share repurchase program, reflecting confidence in its financial prospects despite potential competition in the sector. Net income for the quarter was $306.6 million, up 27% from the previous year, marking a strong financial performance.
Read more →UTHRUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported financial results indicating strong growth for the fourth quarter and the full year of 2023, with revenues reaching a record $2.33 billion, a 20% increase from 2022. The company highlighted achievements in its Tyvaso business, particularly the recent commercial launch of Tyvaso DPI and the FDA clearance for a bioengineered organ clinical study. However, the report also noted a decrease in revenues from its nebulized Tyvaso product and lower international sales of Remodulin.
Read more →UTHRUnited Therapeutics Corporation Reports Third Quarter 2023 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported strong financial results for the third quarter of 2023, with total revenues increasing 18% year-over-year to $609.4 million. The company also saw a net income rise of 12% to $267.6 million. Significant growth was attributed to its treprostinil-based products, particularly Tyvaso DPI, and ongoing clinical studies are poised to further enhance its pipeline. The company anticipates achieving a $4 billion annual revenue run rate by mid-decade, supported by recent expansions in their sales force and product utilization.
Read more →UTHRUnited Therapeutics Corporation Reports Second Quarter 2023 Financial Results SILVER SPRING, Md. and
United Therapeutics Corporation reported its financial results for Q2 2023, revealing a 28% revenue increase to $596.5 million and a net income rise of 123% to $259.2 million, attributed mainly to strong performance from Tyvaso. The company experienced positive feedback on their drug offerings, particularly Tyvaso DPI, which continues to gain traction among patients. Future growth is anticipated with expected launches of new therapies targeting pulmonary conditions. However, the company faces challenges with declining sales of some existing products.
Read more →UTHRUnited Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md. and
United Therapeutics Corporation has successfully won an appeal regarding patent litigation against Liquidia Technologies, with the court affirming that Liquidia's proposed Yutrepia product infringes on United Therapeutics' U.S. Patent No. 10,716,793. Consequently, the FDA is barred from granting approval for Yutrepia until May 14, 2027, unless specific circumstances arise. However, the court did invalidate certain claims of another patent related to treprostinil, which may pose a challenge for United Therapeutics moving forward. Both parties have the opportunity to appeal certain aspects of this ruling.
Read more →UTHRUNITED THERAPEUTICS CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SILVER SPRING, Md. and
United Therapeutics Corporation reported its first quarter 2023 financial results, showcasing a revenue growth of 10%, totaling $506.9 million compared to $461.9 million in Q1 2022. Significant contributions to this growth came from the Tyvaso franchise, which experienced record patient referrals, as well as the performance of Orenitram. The company continues to support its mission with ongoing clinical studies, including those for Tyvaso in idiopathic pulmonary fibrosis and ralinepag for pulmonary arterial hypertension. Overall, the financial outlook appears favorable for the company this quarter.
Read more →UTHRUNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS SILVER SPRING, Md. and
United Therapeutics Corporation reported its financial results for the fourth quarter and full year of 2022, highlighting a record revenue of $1.94 billion. The company noted significant growth in treprostinil-based therapies, especially with the Tyvaso product line, which achieved a milestone in patient numbers. Despite successes, some products like Unituxin and Adcirca faced revenue declines. Moving forward, United Therapeutics aims to double its revenue by 2025, bolstered by ongoing clinical developments and commercial uptake of its therapies.
Read more →UTHRUTHR: A Public Benefit Corporation | January 2023 | 1 United Therapeutics: Enabling Inspiration J.P. Morgan 41 st Annual Healthcare Conference UTHR: A Public Benefit Corporation | January 2023 | 2 Safe Harbor Statement T
United Therapeutics presented at the J.P. Morgan 41st Annual Healthcare Conference, discussing its progress and outlook in pulmonary hypertension treatments, particularly with Tyvaso and Tyvaso DPI. The company successfully doubled the number of patients using Tyvaso, reaching approximately 6,000 by Q4 2022. Additionally, the presentation highlighted advancements in clinical applications and the capabilities of Tyvaso DPI for improved patient outcomes. The event served to educate investors on these developments.
Read more →UTHRDewey Steadman Phone (202) 919-4097 Email ir unither.com United Therapeutics Corporation Reports Third Quarter 2022 Financial Results SILVER SPRING, Md. and
Contact Dewey Steadman Phone (202) 919-4097 Email ir unither.com United Therapeutics Corporation Reports Third Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., November 2, 2022 United Therapeutics Corporation (Nasdaq UTHR), a public benefit
Read more →UTHRUNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON 2 STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Second registration study of Tyvaso (treprostinil) Inhalation S
UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON 2 STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Second registration study of Tyvaso (treprostinil) Inhalation Solution for patients with IPF SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N
Read more →UTHRUnited Therapeutics Prevails in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md., and
United Therapeutics Prevails in Dry Powder Inhaler SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., August 31, 2022 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of De
Read more →UTHRDewey Steadman Phone (202) 919-4097 Email ir unither.com United Therapeutics Corporation Reports Second Quarter 2022 Financial Results SILVER SPRING, Md. and
Contact Dewey Steadman Phone (202) 919-4097 Email ir unither.com United Therapeutics Corporation Reports Second Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 3, 2022 United Therapeutics Corporation (Nasdaq UTHR), a public benefit
Read more →Competitive Position
How UTHR ranks across every disease it competes inCompetitive Position is a premium feature
See how UTHR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial